Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On Demand Treatment and Control of Bleeding Episodes in Subjects With Hemophilia A or Hemophilia B, With Inhibitors: The Crimson 1 Study

NCT04489537 is registered in ClinicalTrials.gov with Catalyst Biosciences as lead sponsor.

NCT NCT04489537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04489537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On Demand Treatment and Control of Bleeding Episodes in Subjects With Hemophilia A or Hemophilia B, With Inhibitors: The Crimson 1 Study
Lead sponsor
Catalyst Biosciences
Phase
Phase 3
Overall status
Terminated
Start date
May 4, 2021
Completion date
December 1, 2021
Enrollment
18 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitor, hemophilia b with inhibitor